Pregnancy Outcomes in Normotensive VS stage1 Hypertension: a Prospective Observational Study

Status: Recruiting
Location: See location...
Intervention Type: Other, Diagnostic test
Study Type: Observational
SUMMARY

In 2017, the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines built on evidence that elevated blood pressure increases cardiovascular mortality in the general population, Reclassification of BP; however, these diagnostic definitions do not include pregnant women, and whether newly diagnosed stage 1 hypertension affects pregnancy complications remains unclear. In this study, the combination of maternal factors, MAP and PLGF was used to comprehensively analyze the risk factors of preeclampsia through the Bayesian rule developed by the British Fetal Medicine Foundation (FMF). According to the guidelines and consensus, the pregnant women were considered to be at high risk when the calculated risk was higher than 1% of the population. To compare the pregnancy outcomes of women with normal blood pressure in the first trimester and stage 1 hypertension in different risk groups, and to find out whether screening for preeclampsia can be omitted for women with normal blood pressure in the first trimester, while screening for preeclampsia should still be performed for women with stage 1 hypertension as an independent moderate risk factor, and finally to optimize the screening strategy for preeclampsia.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 45
Healthy Volunteers: f
View:

• Age ≥18 years old;

• single live fetus with normal NT at 11-14+1 weeks of gestation;

• Blood pressure \< 140/90 mmHg before 14+1 week of gestation;

• Plan to have prenatal examination and delivery in our hospital;

• Sign informed consent.

Locations
Other Locations
China
FANG HE
RECRUITING
Guangzhou
Contact Information
Primary
Fang He, M.D
hefangjnu@126.com
+86 13724831279
Backup
Yafei Wang, Master
542114919@qq.com
+86 18716442633
Time Frame
Start Date: 2024-04-25
Estimated Completion Date: 2026-02-27
Participants
Target number of participants: 626
Treatments
Main study objective Groups: normotensive group
Main study objective Groups: normotensive group
Main study objective Groups: Stage 1 hypertension group
Main study objective Groups: Stage 1 hypertension group
Secondary objective grouping: Stage 1 hypertension low-risk group
Secondary objective grouping: Stage 1 hypertension low-risk group
Secondary objective grouping: Stage 1 hypertension high-risk group
Secondary objective grouping: Stage 1 hypertension high-risk group
Related Therapeutic Areas
Sponsors
Leads: FANG HE

This content was sourced from clinicaltrials.gov